• Clinical/real-world application of PK activators in SCD
• Novel mechanistic studies supporting PK activation as a treatment target for SCD
• Quality of life and assessment of pain measures
• Healthcare resource utilization and other real-world evidence HEOR measures
• Long-term complications, including cognition impairment, and potential role of PK activators
• Prognostic biomarkers for long-term complications, outcomes and organ function
• Characteristics of SCD in neonatal and pediatric populations